mif 2

MIF2-IN-1 (compound 5d) is a potent MIF2 tautomerase inhibitor (IC50: 1.0 μM) that inhibits the proliferation of non-small cell lung cancer cells by arresting the cell cycle through the MAPK pathway, with potential applications in cancer disease studies.

MIF-IN-2 is a heterocyclic macrophage migration inhibitory factor (MIF) inhibitor with anticancer activity for the study of cancer and autoimmune disorders.13460-73-86-5

(±)-CPSI-1306 (2-(3-(2,4-Difluorophenyl)-4,5-dihydroisoxazol-5-yl)-1-morpholinoethan-1-one) is a macrophage migration inhibitory factor (MIF) antagonist and can be used in studies about non-insulin-dependent diabetes mellitus (NIDDM) and the prevention of the deleterious cutaneous effects of acute and chronic UVB exposure.

Boc-MIF-1-Am (compound 2) acts as a human dopamine D2 receptor enhancer with an EC50 value of 17.82 nM and is a bioconjugate of melanostatin (MIF-1) and amantadine. At a concentration of 200 μM, Boc-MIF-1-Am exhibits slight neurotoxicity in SH-SY5Y cells.

4-CPPC is an inhibitor of macrophage migration inhibitory factor-2 (MIF-2; IC50= 27 μM).1It is selective for MIF-2 over MIF-1 (IC50= 450 μM). It inhibits MIF-2, but not MIF-1, binding to CD74in vitrowhen used at a concentration of 10 μM. 4-CPPC (5, 10, and 25 μM) inhibits MIF-2-induced ERK1/2 phosphorylation in primary human skin fibroblasts. 1.Tilstam, P.V., Pantouris, G., Corman, M., et al.A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activityJ. Biol. Chem.294(49)18522-18531(2019)

Iguratimod (T614) is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.

MIF-1 TFA (Melanostatin), an intrinsic brain peptide, serves as a powerful allosteric modulator of the dopamine receptor. It plays a crucial role in regulating melanin production and modifies the analgesic efficacy by inhibiting the opioid receptor's effects. Significantly, MIF-1 TFA can cross the blood-brain barrier (BBB) directly, facilitating its access from the bloodstream to the central nervous system (CNS) [1] [2] [3].

Tyr-W-MIF-1, an opioid tetrapeptide, exhibits both opiate and antiopiate activities, and has been demonstrated to induce analgesia [1] [2] [5].

Iguratimod-d5 is a deuterated compound of Iguratimod. Iguratimod has a CAS number of 123663-49-0. Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.